Clinical Trials on Melanoma (Skin) in South Africa

Total 3385 results

Hoffmann-La Roche

Completed

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Malignant Melanoma

South Africa
Hoffmann-La Roche

Completed

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Malignant Melanoma, Neoplasms

United States, South Africa, Croatia, Brazil, Egypt
University of Sydney
Melanoma and Skin Cancer Trials Limited

Completed

Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. (MEL-SELF)

Melanoma (Skin)

Australia
Hoffmann-La Roche

Completed

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Malignant Melanoma, Neoplasms

Russian Federation, Korea, Republic of, Israel, South Africa, Belarus
Immunocore Ltd

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

Advanced Melanoma

United States, Australia
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin Melanoma

United States, Australia
Melanoma Institute Australia

Withdrawn

Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases (INTRANS)

Melanoma | In-Transit Metastasis of Cutaneous Melanoma

Australia
Castle Biosciences Incorporated

Terminated

Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes (EXPAND)

Cutaneous Melanoma

United States
Merck Sharp & Dohme LLC

Completed

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Melanoma

Australia, South Africa, Spain, Sweden
CancerVax Corporation

Unknown

Vaccine Therapy in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States, Australia
IDEAYA Biosciences

Recruiting

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Uveal Melanoma

United States, Netherlands, Australia, Canada, Italy, France, Germany, United Kingdom
Melanoma and Skin Cancer Trials Limited
Norfolk and Norwich University Hospitals NHS Foundation Trust; Peter MacCallum...

Active, not recruiting

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelMarT)

Cutaneous Melanoma by AJCC V7 Stage

United Kingdom, United States, Sweden, Australia, Canada
National Cancer Institute (NCI)

Completed

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Melanoma (Skin)

United States
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. (IMCODE001)

Advanced Melanoma

United States, Spain, Belgium, Australia, Germany, United Kingdom
Mural Oncology, Inc

Recruiting

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6)

Cutaneous Melanoma | Mucosal Melanoma

United States, Australia, Canada, Italy, Korea, Republic of, Spain, Taiwan, United Kingdom
Aura Biosciences

Recruiting

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

Ocular Melanoma | Uveal Melanoma | Choroidal Melanoma | Indeterminate Lesions

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Not yet recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)

Mucosal Melanoma

Australia
Evaxion Biotech A/S
Novotech (Australia) Pty Limited

Terminated

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Melanoma Stage IV | Melanoma Stage III

Australia
AVAX Technologies

Terminated

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)

Stage II Melanoma

Australia
Hoffmann-La Roche

Completed

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Malignant Melanoma

United States, Australia, Brazil, Spain, South Africa, Ukraine, Bosnia and Herzegovina
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Unresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Melanoma and Skin Cancer Trials Limited
Norfolk and Norwich University Hospitals NHS Foundation Trust; Canadian Cancer... and other collaborators

Recruiting

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (MelMarT-II)

Cutaneous Melanoma, Stage II

United States, Canada, United Kingdom, Australia, Italy, Sweden, Netherlands, New Zealand
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Active, not recruiting

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe)

Melanoma Stage III

Australia
Anthony Joshua, FRACP
St Vincent's Hospital, Sydney

Active, not recruiting

Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma (NADOM)

Ocular Melanoma

Australia
Evaxion Biotech A/S
Merck Sharp & Dohme LLC

Recruiting

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Melanoma Stage IV | Melanoma Stage III

Australia
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States, Canada
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
Immutep Australia Pty. Ltd.

Completed

Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (TACTI-mel)

Stage IV Melanoma | Stage III Melanoma

Australia
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

Australia, United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Melanoma (Skin)

United States
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)

Malignant Melanoma Stage III

United States, Netherlands, Australia
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI); NCIC Clinical Trials Group; Children's Oncology... and other collaborators

Active, not recruiting

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Melanoma (Skin)

United States, Canada, Australia, South Africa
Melanoma and Skin Cancer Trials Limited
Melanoma Institute Australia

Completed

Radiotherapy & Combi in Metastatic Melanoma (CombiRT)

Metastatic Melanoma

Australia
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

United States, Sweden, Australia, France, Italy, South Africa, Spain, United Kingdom, Germany, Netherlands, Israel, New Zealand, Belgium, Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
Idera Pharmaceuticals, Inc.
Bristol-Myers Squibb

Terminated

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Metastatic Melanoma

United States, Canada, Spain, United Kingdom, France, Australia, Germany, Italy, Netherlands, Sweden, Czechia
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Mucosal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
University of Johannesburg

Completed

The Efficacy of Sodium Shale Oil Sulponate 1% Shampoo in the Treatment of Pityriasis Capitis

Dandruff

South Africa
Sanofi

Active, not recruiting

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Malignant Melanoma | Squamous Cell Carcinoma of Skin

Germany, Spain, France, Chile, United States, Australia, Italy
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
Replimune Inc.

Recruiting

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Cancer | NSCLC | Melanoma (Skin) | Microsatellite Instability | Cutaneous Melanoma | Mismatch Repair Deficiency | Non-melanoma Skin Cancer

United States, Spain, France, United Kingdom, Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

Melanoma (Skin)

United States
Ultimovacs ASA

Completed

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Malignant Melanoma

United States, Belgium, United Kingdom, Norway
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X)

Melanoma Stage Iv

Australia, Norway
Immunocore Ltd

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Advanced Melanoma

United States, Australia, Spain, Italy, Germany, Belgium, United Kingdom, Poland, France, Austria, Switzerland
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; SWOG Cancer Research...

Completed

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States

Clinical Trials on Melanoma (Skin) in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations